John Valliant - Jan 4, 2024 Form 4 Insider Report for Fusion Pharmaceuticals Inc. (FUSN)

Role
Chief Executive Officer, Director
Signature
/s/ Maria Stahl as Attorney-in-Fact for John Valliant
Stock symbol
FUSN
Transactions as of
Jan 4, 2024
Transactions value $
$0
Form type
4
Date filed
1/5/2024, 08:41 AM
Previous filing
Jan 9, 2023
Next filing
Jun 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +320K $0.00 320K Jan 4, 2024 Common Stock 320K $8.44 Direct F1
transaction FUSN Restricted Stock Units Award $0 +192K $0.00 192K Jan 4, 2024 Common Stock 192K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in 48 equal monthly installments beginning on February 4, 2024.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock of Fusion Pharmaceuticals Inc. for no consideration.
F3 The restricted stock units vest in six equal installments on each of July 4, 2024, January 4, 2025, July 4, 2025, January 4, 2026, July 4, 2026 and January 4, 2027.